US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Alzinova’s new CEO to BioStock: “The next six months will be really exciting”

Tord Labuda has entered the role as CEO of Alzinova, bringing extensive experience from leading positions in the pharmaceutical industry. The company is in an exciting development phase, as the clinical phase Ib study with the Alzheimer’s vaccine ALZ-101 is expected to be completed in early 2025. In preparation for phase II, Alzinova is actively exploring opportunities for licensing agreements with a larger pharma company.Read the full interview with Tord Labuda at biostock.se: https://www.biostock.se/en/2024/10/alzinovas-new-ceo-the-next-six-months-will-be-really-exciting/ This is a

BioStock: Alzinova's CMO wants to bring forward a vaccine against Alzheimer's

Last fall, Dr Kirsten Harting joined Alzinova as the new Chief Medical Officer (CMO). Harting brings profound expertise from working with brain disorders including Alzheimer’s disease as well as knowledge about vaccines and immunotherapy. Roughly a half year into her tenure as CMO, BioStock reached out to Kirsten to learn more about her ambitions to shape Alzinova’s trajectory as the company advances in its Alzheimer’s clinical trials.Read the full interview with Kirsten Harting at biostock.se: https://www.biostock.se/2024/01/alzinovas-cmo-wants-to-bring-forward-a-vaccine-against-

Alzinova AB interim report January – September 2022

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September 2022Three months, July – September 2022 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to SEK -2,771,286 (SEK -1,455,142). · Earnings per share amounted to SEK -0.09 (SEK -0.09). Nine months, January – September 2022 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to SEK -8,353,042 (SEK -5,096,381). · Earnings per share amounted to SEK -0.26 (SEK -0.32). · Cash and

Alzinova presents its company and projects to investors and international pharmaceutical companies

Alzinova AB (publ) ("Alzinova" or the "Company") will present the Company at both Swedish and international investor meetings during the autumn. The Company will participate in one of the major biotech conferences in Europe, BIO-Europe, which is a forum for partner meetings where the Company will present the vaccine candidate ALZ-101 and the antibody ALZ-201 to potential partners.Alzinova's strategy, to develop an effective and safe treatment for Alzheimer's disease that targets the toxic forms of amyloid beta, the oligomers, has been gaining interest. Preclinical data has documented "best

CSO Anders Sandberg interviewed in BioStock on the development in Alzheimer's research

Alzinova AB (publ) ("Alzinova" or the "Company") announces today that Chief Scientific Officer (CSO) Anders Sandberg is interviewed in a recent article in BioStock where he shares his scientific reflections on the latest developments in the industry.Anders Sandberg, Chief Scientific Officer at Alzinova with many years of experience in protein research with an emphasis on neurotoxic peptide aggregates, is Alzinova's CSO and co-founder of the Company. BioStock contacted Sandberg to learn more about how new research findings are impacting the success of Alzheimer's research and what sets

Alzinova announces new positive safety review of its Phase 1b study in Alzheimer’s disease

Alzinova AB (publ) (“Alzinova” or “the Company”), announces today that a second external safety review has been carried out of the Company's clinical phase 1b study - with a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board ("DSMB"), which continuously reviews the study. Based on the patients included in the study, the DSMB recommends continuing the study as planned without adjustments. The Company has previously communicated DSMB’s first review in April 2022, which also gave the green light to continue the

Alzinova AB interim report January – June 2022

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - June 2022Three months, April – June 2022 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -3,299,600 SEK (-2,179,986 SEK). · Earnings per share amounted to -0.10 SEK (-0.14 SEK). Six months, January – June 2022 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -5,581,756 SEK (-3,641,239 SEK). · Earnings per share amounted to -0.17 SEK (-0.23 SEK). · Equity ratio amounted

Alzinova has recruited half of the patients for the ongoing Phase 1b study of the vaccine candidate ALZ-101

Alzinova AB (publ) (”Alzinova” or “the Company”), announces today that the Phase 1b study for the unique vaccine candidate ALZ-101 against Alzheimer's disease is progressing according to plan and that the Company has now recruited half of the patients to the study where safety and tolerability is tested. The company expects the study to be fully recruited in 2022.Alzinova's Phase 1b study for the vaccine candidate ALZ-101 against Alzheimer's disease continues according to plan and the study has now been recruited to 50%. Full recruitment is expected to be completed in 2022. The vaccine ALZ-

Alzinova establishes scaled-up manufacturing process for ALZ-101 ahead of Phase 2

Alzinova AB (publ) (“Alzinova” or “the Company”) announces today that the Company has successfully verified that the manufacturing process for vaccine doses of ALZ-101, the Company’s vaccine candidate against Alzheimer’s disease, can be scaled up to deliver larger production volumes required for clinical phase 2 trials.Preparations for clinical phase 2 development are progressing successfully and the Company has now verified that the manufacturing process can produce larger volumes of Alzinova's Alzheimer's vaccine candidate ALZ-101. Earlier this year, Alzinova announced that it had already

Conversion of BTU into shares and warrants of series TO3

The rights issue of units announced on 19 April 2022 (the “Rights Issue”) in Alzinova AB (publ) (“Alzinova” or the “Company”) has now been registered with the Swedish Companies Registration Office. The outcome of the Rights Issue was announced by press release on 15 June 2022.The last day of trading with paid subscribed unit (BTU) is on 6 July 2022. The record date for the conversion is on 8 July 2022, after which BTU will be converted into shares and warrants of series TO3. Shares and warrants subscribed for in the Rights Issue is expected to be available on the subscriber's custodian/VP

Alzinova announces outcome of rights issue

Alzinova AB (publ) (“Alzinova” or the “Company”) has completed the rights issue of units, consisting of shares and warrants of series TO3, which was announced by press release on 19 April 2022 (the “Rights Issue”). The Rights Issue has been subscribed for to a total of 80.00 percent, of which approximately 56.17 percent was subscribed for by use of unit rights, and approximately 6.16 percent was subscribed for without use of unit rights. Approximately 17.67 percent was subscribed for by underwriters.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,

Alzinova appoints Mangold Fondkommission as new liquidity provider

Alzinova AB (”Alzinova” or the ”Company”) has appointed Mangold Fondkommission AB (”Mangold”) as liquidity provider for the Company’s shares, listed on Nasdaq First North Growth Market (”Nasdaq First North”). The purpose of the liquidity provider, is to improve the liquidity of the share and reduce the difference between the buying and selling price. The assignment commences on 8 June, 2022.A liquidity provider aims to provide a more correct price picture in the Company’s share. Mangold will fulfil its assignment as liquidity provider to ensure the possibility of trading in Alzinova’s share

The subscription period in Alzinova’s rights issue starts today

Today, on 30 May 2022, the subscription period begins for Alzinova AB’s (publ) (“Alzinova” or the “Company”) rights issue of unit consisting of shares and warrants, which was announced on 19 April 2022 (the “Rights Issue”). The subscription period in the Rights Issue runs up to and including 13 June 2022. However, please note that nominees may have a deadline for subscription in the Rights Issue that falls before 13 June 2022.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA,

Alzinova initiates development of a stable cell line to prepare the monoclonal antibody ALZ-201 for Alzheimer’s clinical trials

Alzinova AB (publ) (“Alzinova” or the “Company”) today announces the initiation of the next step in the preclinical development of its oligomer-specific monoclonal antibody, ALZ-201. The Company is developing ALZ-201 as a second product in its portfolio of Alzheimer’s treatments, along with its vaccine candidate, ALZ-101, which is currently in Phase 1b clinical development.The Company has now initiated the development of a stable cell line to produce high and consistent levels of ALZ-201. In this process, the goal is to isolate single, viable, and high-producing cell clones to ensure

Alzinova publishes prospectus in connection with rights issue of units

Alzinova AB (publ) (“Alzinova” or the “Company”) has prepared an EU growth prospectus (the “Prospectus”) in connection with the rights issue of units consisting of shares and warrants which was announced through a press release on 19 April 2022 (the “Rights Issue”). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SWITZERLAND,

Bulletin from the annual general meeting of Alzinova AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Alzinova AB (publ) (“the Company”) on 18 May in Gothenburg.Adoption of income statement and balance sheet and discharge from liabilityThe AGM resolved to adopt the income statement for the financial year 2021 as well as the balance sheet as of 31 December 2021. The members of the board of directors and the managing director were discharged from liability for the financial year 2021. Allocation of profit or lossThe AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall

Alzinova announces positive safety review and continuation of its Phase 1b study in Alzheimer’s disease

Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers, today announces that the Data and Safety Monitoring Board (DSMB) completed a planned assessment of the ongoing ALZ-101 Phase 1b clinical study and recommended continuation of the study.The DSMB consists of independent group of experts who review data during the study, with particular attention to safety. The data are kept within the DSMB group and may not be revealed to the company, unless action is necessary regarding the

Notice of annual general meeting in Alzinova AB (publ)

The shareholders of Alzinova AB (publ) reg. no. 556861-8168 (the “Company”) are hereby summoned to attend the Annual General Meeting (the “AGM”) on 18 May 2022 at 14.00 CEST at Stenasalen in Ågrenska villan at the university of Gothenburg (address Högåsplatsen 2) in Gothenburg. Registration starts at 13.30 CEST.Right to participateShareholders that wish to participate in the AGM shall be registered in the share register maintained by Euroclear Sweden AB no later than on 10 May 2022 and shall have notified the Company of their intention to participate at the AGM no later than on 12 May

The Board of Directors resolves on a rights issue of units of approximately SEK 42.5 million, part of the issue proceeds is intended to finance further development of ALZ-201

The Board of Directors of Alzinova AB (publ) (“Alzinova” or “the Company”) has today, subject to the subsequent approval of the Annual General Meeting which is to be held on 18 May 2022, resolved on an issue of units consisting of shares and warrants of series TO3 (the “Warrants”) with pre-emption rights for the shareholders of approximately SEK 42.5 million (the “Rights Issue”), and resolved to propose that the Annual General Meeting amends the Company’s Articles of Association regarding the limits for the number of shares and the share capital. The Rights Issue is covered to approximately

Alzinova AB interim report January – March 2022

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2022Three months, January – March 2022 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -2,282,156 SEK (-1,461,253 SEK). · Earnings per share amounted to -0.14 SEK (-0.09 SEK). · Equity ratio amounted to 91.4% (93.6%). Significant events during January – March 2022 · Alzinova announced in January 2022 that the company had completed work on adapting the antibody to humans and selected a main candi­date

Alzinova publishes the Annual Report for 2021

Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing disease-modifying treatments for Alzheimer’s, today announces that the Company’s 2021 Annual Report has been published.“2021 was a successful year for Alzinova when we started the first clinical study with the therapeutic vaccine, ALZ-101, in Alzheimer’s patients and we established new collaborations with leading groups in the fight against Alzheimer’s,” says Kristina Torfgård, CEO of Alzinova. The Annual Report, which is attached in the press release, can also be downloaded from the company’s Swedish website, www.

Alzinova improves manufacturing process of ALZ-101 to meet phase 2 requirements

Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing disease-modifying treatments for Alzheimer’s, today announces that the manufacturing process for its oligomer-specific vaccine, ALZ-101, has been further improved to facilitate large-scale production.Alzinova’s drug substance manufacturing partner, Bachem (Bubendorf, Switzerland), has optimised the manufacturing process of the active ingredient in ALZ-101 – a vaccine in clinical development for the treatment of Alzheimer’s disease. Process optimisations have resulted in a more efficient and scalable manufacturing

Alzinova AB Year end report 2021

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year end report for the period January - December 2021Twelve months, January – December 2021 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -7,552,006 SEK (-6,499,557 SEK). · Earnings per share amounted to -0.48 SEK (-0.41 SEK). · Equity ratio amounted to 96.5% (95.2%). Three months, October – December 2021 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -2,455,624 SEK (-2,361,085 SEK). · Earnings per share

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe